Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
USA-based Novelos Therapeutics (OTCQX: NVLT), which is developing novel drugs for the treatment and diagnosis of cancer, has announced the closing of a private placement of equity securities to an affiliated entity of Renova Group, a leading Russian private business group, for gross proceeds to Novelos of $2 million. 8 November 2012
Pharmaceutical
A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results. It was sponsored by the USA's Amylin and partner Eli Lilly. Amylin is the manufacturer of Bydureon, the exenatide preparation that was used in this study. Results of the study were published on-line ahead of print on November 7, by The Lancet. 8 November 2012
Pharmaceutical
The US Food and Drug Administration yesterday published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications for Danish diabetes major Novo Nordisk's (NOV: N) insulin degludec and insulin degludec/insulin aspart, which will take place on November 8. 6 November 2012
Biotechnology
US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the USA, represents one of the most significant investments in Lilly's USA-based manufacturing operations in the past decade. 2 November 2012
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) today reported financial results for the first nine months of 2012 with 18% growth in sales to 57.1 billion Danish kroner ($9.9 billion), driven by 21% (14%local currencies) growth in insulins, 74% (64%lc) growth in Victoza (liraglutide). Operating profit leapt 34% (21%lc) to 21.9 billion kroner. Net profit increased 26% to 15.68 billion kroner and earnings per share rose 31% to DKK 28.32. 31 October 2012
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG: SIX), has entered into license agreements for its original compound SGLT2 inhibitor CSG452, for which Chugai is currently conducting clinical development for type 2 diabetes, with Japan's privately-owned Kowa and France's Sanofi (Euronext: SAN), in Japan. 29 October 2012
Generics
US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) said on Friday that it has launched a generic version of Japanese drug major Takeda's (TYO: 4502) type 2 diabetes drug Actos (pioglitazone 15mg, 30mg and 45mg tablets) after receiving final approval from the US Food and Drug Administration, and began shipping the product immediately. 29 October 2012
Pharmaceutical
Denmark-based insulin giant Novo Nordisk (NOV: N) late yesterday announced that the US Food and Drug Administration has published information relating to the focus of the Advisory Committee meeting scheduled for November 8 to discuss the New Drug Applications for the company's ultra-long acting insulin degludec and insulin degludec/insulin aspart. 26 October 2012
Pharmaceutical
The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011 to more than $550 million in 2016, according to a new report from health care advisory firm Decision Resources, titled Type 2 Diabetes in South Korea. 23 October 2012
Pharmaceutical
US pharma major Eli Lilly (NYSE: LLY) reported positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes. 22 October 2012
Pharmaceutical
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced its positive opinions, recommending marketing authorizations for Danish insulin giant Novo Nordisk's (NOV: N) Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes mellitus in adults. 22 October 2012
Biotechnology
Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell 3% to $149.50 in premarket trading yesterday, when the company said that the US Food and Drug Administration has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application for the marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis (MS). 19 October 2012
Pharmaceutical
The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion in 2011 to nearly $50 billion in 2021 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from Decision Resources. The main factors fueling this growth are an increasing drug-treated patient population and a large pipeline of products expected to launch during this period. 16 October 2012
Biotechnology
More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa within the first 12 months of launch. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoiesis-stimulating Agents, Insulin, and Human Growth Hormone from Decision Resources BioTrends unit, US nephrologists' predicted speed of uptake is on a par with uptake rates reported among surveyed German nephrologists who have one of the highest usage rates of biosimilar epoetin alfa across Europe. 9 October 2012
Pharmaceutical
China has the largest prevalent population of type 2 diabetes in the world and an ever-expanding affluent middle class, while South Korea has one of the most advanced healthcare systems in the world, notes a new report from health care advisory firm Decision Resources. 4 October 2012
Biotechnology
In what turns out to be a very busy couple of days for French drug major Sanofi (Euronext: SAN), the company announced an acquisition, revised terms for an off patent best-seller and presented strong clinical data on two of its drugs. 3 October 2012
Pharmaceutical
New data presented yesterday at the Annual Meeting of the European Association for the Study of Diabetes (EASD), being held in Berlin, Germany, show that patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycemia when using Danish diabetes major Novo Nordisk's (NOV: N) insulin degludec compared with those using insulin glargine (0.27 [insulin degludec] versus 0.46 [insulin glargine] episodes per patient per year, p<0.001) with equivalent improvements in glucose control. 3 October 2012
Pharmaceutical
There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday, the first of which was good news for German drug major Bayer (BAYN: DE) and US partner Regeneron (Nasdaq: REGN), with the news that the regulator has approved the companies' Eylea (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). 1 October 2012
Biotechnology
Phase IIa data on Switzerland-based Evolva's (SIX: EVE) EV-077 indicate that it has significant potential in treating the complications of diabetes, if a safety concern can be overcome, comment analysts at Edison Investment Research. 30 September 2012
Pharmaceutical
Australia's CSL Limited (ASX: CSL) has developed a new drug candidate - dubbed 2H10 - that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease. 28 September 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze